Autore/Fonte: A. Montonati, M. Parenti, S. Dubini, M. Monti, G. Scienza, G. Clerici, A. Sessa
Conoscenze e attitudini dei medici di medicina generale nei confronti della terapia anticoagulante orale
Leggi →
Dicembre 2022
Questo è quello che abbiamo trovato per te
Autore/Fonte: A. Montonati, M. Parenti, S. Dubini, M. Monti, G. Scienza, G. Clerici, A. Sessa
Andrologi, colpiti da ‘sindrome del lenzuolo’ in 4 milioni
Sono rivolte alla medicina territoriale e ospedaliera per favorire un uso ottimale degli antibiotici
Sono rivolte alla medicina territoriale e ospedaliera per favorire un uso ottimale degli antibiotici
Sono rivolte alla medicina territoriale e ospedaliera per favorire un uso ottimale degli antibiotici
Introduction
The incidence of degenerative disorders, including osteoarthritis (OA), increases rapidly in women after menopause. However, the influence of the menopause is still insufficiently investigated due to the slowness of menopausal transition. In this study, a novel human model is used in which it is expected that menopausal-related changes will occur faster. This is the Females discontinuing Oral Contraceptives Use at Menopausal age model. The ultimate aim is to link these changes to OA and other degenerative disorders, including cardiovascular diseases, diabetes, osteoporosis and tendinopathies.
Methods and analysis
This is a pilot observational prospective cohort study with 2 years of follow-up. Fifty women aged 50–60 who use oral contraceptive (OC) and have the intention to stop are included. Measurements are performed once before stopping OC, and four times thereafter at 6 weeks, 6 months, 1 year and 2 years. At every time point, a questionnaire is filled in and a sample of blood is drawn. At the first and final time points, a physical examination, hand radiographs and a MRI scan of one knee are performed. The primary OA outcome is progression of the MRI Osteoarthritis Knee Score. Secondary OA outcomes are the development of clinical knee and hand OA, development of knee OA according to the MRI definition, and progression of radiographic features for hand OA. Principal component analysis will be used to assess which changes occur after stopping OC. Univariate and multivariate generalised estimating equation models will be used to test for associations between these components and OA.
Ethics and dissemination
The study has been approved by the Medical Ethics Committee of the Erasmus MC University Medical Center Rotterdam (MEC-2019-0592). All participants must give informed consent before data collection. Results will be disseminated in national and international journals.
Trial registration number
NL70796.078.19.
Potenziale cura per cardiomiopatia amiloide da transtiretina
Annals of Internal Medicine, Ahead of Print.
Studio pilota, a Milano le frontiere della ‘digital health’
Autore/Fonte: ASCO/SIO
Autore/Fonte: Intensive Care Med
L’interruzione precoce del trattamento con statine potrebbe ridurre sostanzialmente la […]
Objectives
We aimed to describe the characteristics and to compare the sex differences in the clinical features and prognosis of Chinese elderly patients with senile degenerative valvular heart disease (VHD).
Design
This study was a nationwide, multicentre, prospective cohort study.
Setting
Participants were enrolled consecutively from 69 hospitals nationwide in China from September to December 2016.
Participants
A total of 2728 patients aged ≥60 years old with an aetiological diagnosis of moderate to severe degenerative VHD as defined by echocardiography were recruited.
Main outcome measures
The baseline data and 1-year follow-up data were collected, and disease distribution, clinical features, treatment and prognosis were compared between different sex groups.
Results
Aortic disease was more common in men, and mitral disease was more common in women. Male patients were more likely to have smoking, coronary heart disease, cardiomyopathy, chronic obstructive pulmonary disease and coronary artery bypass grafting histories, while female patients had more hypertension and atrial fibrillation. The average age and left ventricular ejection fraction were significantly lower in men than in women (p
Introduction
Degenerative cervical myelopathy (DCM) is the most common cause of spinal cord impairment. Unfortunately, the condition remains poorly recognised and underdiagnosed. To better identify patients, screening tests that target individuals at high risk would be helpful. One group in particular known to have a high prevalence of DCM consists of patients with lumbar degenerative disease (LDD), with the combined presentation referred to as tandem stenosis. Given that LDD is one of the most common presentations in neurosurgical practice and primary care, it is the objective of the proposed study to administer a screening test to these patients as well as those with risk factors or symptoms which raise the suspicion of underlying DCM.
Methods and analysis
A screening test based on clinical signs/symptoms and known risk factors of DCM was designed. Screening will be performed in neurosurgical consultations for patients with LDD or those with any suspicion of myelopathy. Points are attributed based on the presence of signs/symptoms of DCM (eg, Hoffmann sign, hyper-reflexia) and for comorbidities that predispose or are frequently associated with cervical myelopathy (eg, rheumatoid arthritis, carpal tunnel syndrome). Patients with ≥3 points undergo cervical MRI examination. Patients with positive MRIs will be consulted and receive assessment via modified Japanese Orthopedic Association and Neck Disability Index scores, and subsequent clinical management will be based on practice guidelines. An exploratory multivariate analysis of the effectiveness and efficiency of this proposed screening test will be evaluated after positively screening 50 patients for DCM.
Ethics and dissemination
This study has received research ethics approval from the Swiss Association of Research Ethics Committees (ID: 2020-02785). The results of this study will be disseminated in a journal targeting physicians commonly encountering patients with LDD.
Autore/Fonte: JAMA Oncology
Autore/Fonte: Nuffield Department of Clinical Neurosciences di Oxford